Evogene (EVGN) Expected to Announce Earnings on Wednesday

Evogene (NASDAQ:EVGN) is projected to release its Q1 2025 earnings data before the market opens on Wednesday, May 21st. Analysts expect Evogene to post earnings of ($0.51) per share and revenue of $4.42 million for the quarter.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.78. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. The business had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $3.63 million. During the same quarter in the prior year, the business earned ($1.30) EPS.

Evogene Trading Up 2.3%

EVGN opened at $1.34 on Tuesday. Evogene has a 1-year low of $0.95 and a 1-year high of $9.00. The stock’s fifty day simple moving average is $1.20 and its 200 day simple moving average is $1.45. The stock has a market cap of $7.19 million, a PE ratio of -0.30 and a beta of 1.55.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Evogene stock. Jane Street Group LLC raised its position in Evogene Ltd. (NASDAQ:EVGN) by 58.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,732 shares of the biotechnology company’s stock after buying an additional 12,387 shares during the quarter. Jane Street Group LLC owned 0.63% of Evogene worth $42,000 at the end of the most recent reporting period. 10.40% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have commented on EVGN. Alliance Global Partners reaffirmed a “buy” rating on shares of Evogene in a report on Friday, March 7th. StockNews.com began coverage on Evogene in a report on Tuesday, May 13th. They issued a “sell” rating on the stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.